Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.

OBJECTIVE Increased low density lipoprotein (LDL) cholesterol and triglycerides, and decreased high density lipoprotein (HDL) cholesterol concentrations are associated with adverse cardiovascular risk in the general population. Patients with systemic lupus erythematosus (SLE) have an altered lipid profile characterized by increased triglycerides and decreased HDL cholesterol concentrations. We examined the relationships between lipid concentrations, cytokines, and inflammatory markers in patients with SLE. METHODS Fasting lipid concentrations, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured in 110 patients with SLE. Disease activity was quantified by the SLE Disease Activity Index (SLEDAI), and disease damage by the Systemic Lupus International Collaborating Clinics (SLICC) score. Concentrations of circulating tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and insulin were measured and insulin sensitivity calculated. RESULTS Lower concentrations of HDL cholesterol were independently associated with higher ESR (p < 0.001), IL-6 (p = 0.02), SLEDAI (p = 0.04), and TNF-alpha (p = 0.04) after adjustment for age, sex, race, body mass index, insulin sensitivity, and current use of corticosteroids or hydroxychloroquine. Triglyceride concentrations were associated with higher CRP concentrations (p = 0.02) and SLICC score (p = 0.04). CONCLUSION Deleterious changes in lipid profile are independently associated with higher concentrations of markers and mediators of inflammation and disease activity and damage in patients with SLE.

[1]  S. Bandinelli,et al.  High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. , 2007, Atherosclerosis.

[2]  P. Raggi,et al.  High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors , 2006, Annals of the rheumatic diseases.

[3]  P. Raggi,et al.  Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus , 2006, Lupus.

[4]  K. Kalunian,et al.  Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[5]  C. Greenwood,et al.  Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[6]  E. Bonfá,et al.  Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus , 2006, Clinical & developmental immunology.

[7]  A. Drosos,et al.  Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study , 2006, Arthritis research & therapy.

[8]  P. Raggi,et al.  Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. , 2006, The Journal of rheumatology.

[9]  D. Borderie,et al.  Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[10]  O. Johnson,et al.  Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy , 2006, Scandinavian journal of rheumatology.

[11]  I. Bruce,et al.  Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. , 2006, Journal of Rheumatology.

[12]  M. H. Ahmed.  Chloroquine-induced nitric oxide improves insulin sensitivity in rheumatoid arthritis. , 2006, Medical hypotheses.

[13]  P. Raggi,et al.  Endothelial Function in Systemic Lupus Erythematosus: Relationship to Disease Activity, Cardiovascular Risk Factors, Corticosteroid Therapy, and Coronary Calcification , 2005, Vascular health and risk management.

[14]  C. Stein,et al.  Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[15]  B. Dijkmans,et al.  Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[16]  Eduardo Esteve,et al.  Dyslipidemia and inflammation: an evolutionary conserved mechanism. , 2005, Clinical nutrition.

[17]  J. Ramires,et al.  Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. , 2004, Atherosclerosis.

[18]  E. Borba,et al.  Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? , 2004, Arthritis and rheumatism.

[19]  M. Reilly,et al.  Measures of Insulin Resistance Add Incremental Value to the Clinical Diagnosis of Metabolic Syndrome in Association With Coronary Atherosclerosis , 2004, Circulation.

[20]  J. Fruchart,et al.  Atherogenic Lipoprotein Particles in Atherosclerosis , 2004, Circulation.

[21]  Paolo Raggi,et al.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[22]  J. Schwartz,et al.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[23]  L. Klareskog,et al.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[24]  B. Joffe,et al.  Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[25]  G. Hughes,et al.  Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. , 2003, Journal of lipid research.

[26]  M. Reichlin,et al.  Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[27]  K. Matthews,et al.  Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. , 2002, The American journal of cardiology.

[28]  F. Formiga,et al.  Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients , 2001, Lupus.

[29]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[30]  K. Feingold,et al.  Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.

[31]  J. Ramires,et al.  Chylomicron metabolism is markedly altered in systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[32]  I. Bruce,et al.  The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. , 1999, The Journal of rheumatology.

[33]  M. Ward.  Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[34]  J. L. Carrillo,et al.  Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[35]  H. Lithell,et al.  Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[36]  E. Bonfá,et al.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies , 1997, Lupus.

[37]  D. Gladman,et al.  Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. , 1997, The Journal of rheumatology.

[38]  H. Krumholz,et al.  Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. , 1997, Circulation.

[39]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[40]  W. Emlen,et al.  Serum and urinary interleukin-6 in systemic lupus erythematosus , 1996, Lupus.

[41]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[42]  D. Gladman,et al.  Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. , 1995, The Journal of rheumatology.

[43]  E. Harris,et al.  The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.

[44]  K. Feingold,et al.  Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. , 1994, Lymphokine and cytokine research.

[45]  B. Ryffel,et al.  Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. , 1994, The American journal of pathology.

[46]  L. Magder,et al.  Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. , 1994, The American journal of medicine.

[47]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[48]  L. Wide,et al.  Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment. , 1987, Metabolism: clinical and experimental.

[49]  A. Goldberg,et al.  Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. , 1987, The American journal of medicine.

[50]  W. Kannel,et al.  Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. , 1986, American heart journal.

[51]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.